Truist Financial Corp Sells 37,658 Shares of Progyny, Inc. (NASDAQ:PGNY)

Truist Financial Corp decreased its holdings in shares of Progyny, Inc. (NASDAQ:PGNYGet Rating) by 65.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,242 shares of the company’s stock after selling 37,658 shares during the period. Truist Financial Corp’s holdings in Progyny were worth $751,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. National Bank of Canada FI bought a new stake in Progyny during the second quarter worth about $29,000. Lazard Asset Management LLC bought a new stake in Progyny during the first quarter worth about $62,000. Castle Wealth Management LLC bought a new stake in Progyny during the second quarter worth about $63,000. Parkside Financial Bank & Trust bought a new stake in Progyny during the first quarter worth about $70,000. Finally, Captrust Financial Advisors lifted its stake in shares of Progyny by 25.0% in the 1st quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock valued at $107,000 after acquiring an additional 418 shares during the last quarter. Institutional investors own 86.12% of the company’s stock.

Insider Transactions at Progyny

In other news, Director Norman Payson sold 6,617 shares of Progyny stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total value of $209,428.05. Following the completion of the transaction, the director now owns 279,063 shares of the company’s stock, valued at approximately $8,832,343.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Norman Payson sold 6,617 shares of Progyny stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total value of $209,428.05. Following the completion of the transaction, the director now owns 279,063 shares of the company’s stock, valued at approximately $8,832,343.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman David J. Schlanger sold 25,989 shares of Progyny stock in a transaction dated Tuesday, October 25th. The stock was sold at an average price of $39.62, for a total value of $1,029,684.18. Following the completion of the transaction, the chairman now directly owns 82,548 shares of the company’s stock, valued at approximately $3,270,551.76. The disclosure for this sale can be found here. Insiders sold a total of 123,966 shares of company stock valued at $4,787,473 in the last quarter. 14.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PGNY shares. KeyCorp decreased their price target on Progyny from $55.00 to $45.00 and set an “overweight” rating on the stock in a research note on Monday, December 19th. JPMorgan Chase & Co. cut their target price on shares of Progyny from $78.00 to $62.00 and set an “overweight” rating on the stock in a report on Friday, November 18th. TheStreet upgraded shares of Progyny from a “d+” rating to a “c” rating in a report on Monday, October 24th. Finally, SVB Leerink restated a “market perform” rating and issued a $34.00 target price (down previously from $59.00) on shares of Progyny in a report on Thursday, January 5th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.25.

Progyny Trading Down 0.8 %

Shares of Progyny stock opened at $33.02 on Friday. The firm has a market capitalization of $3.07 billion, a P/E ratio of 78.62, a P/E/G ratio of 4.25 and a beta of 1.59. The business has a fifty day simple moving average of $32.68 and a two-hundred day simple moving average of $36.32. Progyny, Inc. has a 12 month low of $25.67 and a 12 month high of $53.10.

Progyny (NASDAQ:PGNYGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.05 by $0.08. The business had revenue of $205.37 million during the quarter, compared to analyst estimates of $194.41 million. Progyny had a return on equity of 14.14% and a net margin of 6.00%. Analysts predict that Progyny, Inc. will post 0.29 earnings per share for the current year.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Stories

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.